The most recent global report from the United Nations states that by 2030 the global population will reach 8.6 billion . This predicted growth in global population presents many potential problems. Some of these problems are obvious; shelter, food etc…
What about Healthcare? Did you know that currently for every 1,000 healthcare patients there are only 3 doctors available to provide treatment ?
This massive shortcoming in patient care has created a serious problem for patients and healthcare providers! It has also opened the doors wide open for companies – and investors – to immediately capitalize. Companies in the healthcare sector are making key investments in telemedicine and machine learning to take the quality of care to the next stage.
THE PROBLEM: The Health Care System is Dated & Broken!
- Rising Costs: Governments and payors facing increasing costs that are simply unsustainable.
- Inefficient Use of Resources: 39% of Canadians who visited an ER indicated that they could have avoided the visit if they had better access to primary care.
- Doctor Supply: A shortage of primary care doctors and nurses, especially in remote and rural communities, leads to clinician burn out and patients frustrated by long wait times. Newly licensed doctors are avoiding primary care because of these dynamics, which increases the pressure on an already stressed system.
- Accessibility: Approximately 15% of Canadians aged 12 and older don’t have a primary care physician. Nearly two-thirds (59%) of seniors are unable to get a same-or next-day appointment. Almost 7 in 10 Canadians avoid seeing a doctor when they are sick.
THE PREMIER HEALTH SOLUTION:
- On Your Time: Patients can book appointments & be seen by general practitioners & specialists 24/7.
- Ease of Access: Patients, Doctors, Nurses & Pharmacists can review your medical chart in real-time, anytime.
- No Borders: Doctors can be anywhere in the world and still see their patients. Patients can visit any clinic and have their medical charts follow them.
- At Your Convenience: Prescriptions electronically submitted to the pharmacy of their choice or delivered free to them by a preferred pharmacy partner.
The public is beginning to take notice of Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI). The company has nearly 3,000,000 (three million) patients, an ecosystem of 290 clinics, and 4,600 licensed practitioners. (OTC: PHGRF) / (CSE: PHGI) is Connecting the human skill-based expertise with proprietary Artificial Intelligence, Premier is positioning to be a leading force in this rapidly expanding digital health industry, right now!
Premier’s Industry-Changing Intelligence
When it comes to healthcare technology, there have been few moonshot moments that have dramatically changed the face of the industry. While the healthcare juggernauts work to simply expand their reach with archaic technology, Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) has identified an open opportunity to capitalize on.
It Starts With Industry-Leading Technology
Through the use of HealthVue, a wholly-owned subsidiary of Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI), has built a medical ecosystem with the ability to directly connect to pharmacists, nurses, and physicians in real time. With a high number of family physicians quitting and high overhead, doctors are beginning to avoid private practices entirely. This is a HUGE problem especially in countries that actually have “Free Healthcare” like Canada.
In other cases, smaller clinics don’t have the resources for adequate patient follow-up. Implementing Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI)’s systematic process could significantly improve the quality of care and improve patient health outcomes.
Acquisitions & Strategic Ventures Target Substantial Growth Opportunities For Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI)
Unlike most micro-cap companies, Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) is in the prime position to take a page out of the industry’s leading corporations. What do we mean? Premier Health is hot on the trail of strategic ventures and acquisitions right now.
On January 29, Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) closed on one of its biggest acquisitions to date and brought on CLoud Practice Inc. For someone new to this story, what does this actually mean?
This acquisition brings on several key assets:
- Juno EMR (Electronic Medical Record) Cloud-Based Solution.
- ClinicAid, a Medical Billing Software.
- MyHealthAccess, an Online Patient Portal.
More importantly, Juno’s EMR, in particular, gives Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) access to a system that is currently used by, 287 Clinics, over 3,000 Licensed Practitioners, 1,500 Medical Staff, and 2,870,000 Registered Patients. What’s more, is that the company has just beefed up its technology team in order to deliver a patient-centric platform and mobile app with a beta version becoming available by end of Q2.
This Gets So Much Better… the medical billing software, ClinicAid, processes upwards of $30,000,000 in payments to over 3000 health providers EACH MONTH. This acquisition gives Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) immediate access to added cash flow and earnings growth.
The Cannabis Connection: No Longer a Low Tide For Cannabis & Premier Is Setting Its Sights
We are seeing a tidal shift in public opinion regarding the cannabis sector and the potential benefits of incorporating medicinal cannabis and CBD into healthcare. Leaping ahead, Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) announced in late 2018 plans for launching a Cannabis Clinic.
Dr. Essam Hamza, CEO of Premier Health, shared that “the role of Cannabis in treating medical conditions is continuously expanding. Our doctors have had success in treating patients with various ailments from chronic pain to cancer-related symptoms. There is a gap between the patient’s need for medical marijuana, and the family doctor’s comfort and knowledge to prescribe it.”
The Canadian medical cannabis market is estimated to be worth approximately $2.35 billion by 2025  and Premier is already diversifying its revenue potential.
The Evolution Continues With New, Cutting Edge Technology
Let’s paint this picture for you: Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) has access to MILLIONS of patients and is now at the forefront of a significant pivot for healthcare and cannabis.
Traditionally, there are two types of patients right now: medical patients who are brand new to medical cannabis and others who are active users that are well aware of the benefits. Being that there are currently 4,600 physicians & healthcare practitioners who use Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI)’s Juno EMR platform, this latest agreement could mean big opportunities for Premier. Why is all of this important?
CB2 Insights just integrated its technology with Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI). And why this deal could be big for Premier is based on CB2 and its unique technology platform that could drastically change the medical cannabis industry. Let’s explain:
Access to knowledgeable practitioners is a huge hurdle for the medical cannabis industry.
The Premier Solution & A First To Market Opportunity?
Not only does the latest deal open up a major opportunity for a company like CB2, it effectively brings Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) to the forefront to offer an all-inclusive platform for nearly 5,000 doctors & healthcare practitioners to prescribe medical cannabis to millions of patients across North America.
The unique feature of the CB2 Clinical Decision Support (CDS) tool is that the technology dramatically cuts the learning curve for medical providers. Those who may not be completely educated on different variants of cannabis can efficiently determine a proper strain/product for patients based on thousands of datapoint collected by CB2’s platform.
“We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner.”
CB2 gathers data at the point-of-care in a HIPAA-compliant manner, both aggregated and anonymized, to study trends and outcomes that work to educate and support stakeholders including but not limited to physicians and other healthcare professionals. Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) essentially becomes the gatekeeper to millions of patients and, now thousands of practitioners who can feel comfortable prescribing different medical cannabis based on the results from CB2’s CDS Tool.
Latest News (3/27/2019):
Premier Health (OTC: PHGRF) (CSE: PHGI) Signs Agreement with CB2 Insights to Integrate Medical Cannabis Clinical Decision Support Tool
Traditional Health Care Is Transforming
In recent months, healthcare companies have explored integrating augmented reality technology into care offerings. According to recent reports, the healthcare-based AR market is projected to be worth over $5 billion by 2025 .
Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) is investing in augmented reality technology to be at the forefront of this new opportunity. Premier dominated headlines when the Company’s executive leadership team announced plans to collaborate with NexTech AR Solutions to explore bringing AR technology to its patient-centric healthcare app.
Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) will work with NexTech to develop educational tools for healthcare professionals and patients through the use of augmented reality technology. The potential applications of AR in training medical professionals are endless because the tech creates an incredibly engaging educational experience.
Imagine medical professionals being able to take their anatomical education one step further by interacting with a virtual representation of the human heart, and demonstrate to their patients exactly what is going on internally.
“At Premier Health, we pride ourselves on being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient-centric telemedicine app. AR has the potential to revolutionize both the access to data and the delivery of healthcare. The technology will help doctors and patients alike — doctors will have access to the latest and most relevant information about their patients while patients can use AR for self-education and improving the quality of treatment they receive.”
Furthermore, the company’s research pilot study with Bio Conscious Technologies could deliver yet another layer of Artificial Intelligence to power Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI)’s market-leading clinical decision support software, Juno Electronic Medical Records.
Premier Health (PHGRF) (PHGI) to Pilot Bio Conscious Technologies AI Powered Remote Patient Monitoring Tool
The research pilot will use data from patients who are using the app and sign up for the study. The data used will include sugar levels, heart rate, blood pressure, age, sex and weight – much of which is collected from the integration of the patient’s health monitoring devices such as their smartwatch. The Diabits tool will then tailor a personalized blood sugar model which the patient can use to guide their nutrition and exercise plan.
Just as Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) did with its Cloud Practice acquisition, it has continued to execute on with other irons in the fire. Furthermore, Premier isn’t just focusing on cloud-based tech but also on brick and mortar. Earlier in 2019, the company entered into a letter of intent to acquire 2 operating pharmacies doing about $6 million in revenue and were cash flow positive.
On April 2 Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) entered into a formal agreement to complete this acquisition! This isn’t just some random brick and mortar business; we’re talking a business doing about $6 million in revenue. Premier Health expects to complete the acquisition during the second quarter of 2019. Those looking at Premier Health Group right now are seeing it at the exact moment of several huge milestones and this is one of them.
What could be even better yet is that this deal could seamlessly integrate with EVERYTHING else that the company has in place…and the CEO agrees:
“We look forward to working together to improve fulfillment for our rapidly growing patient base. In light of our recent announcement of our medical cannabis decision tool for our JUNO EMR clients, our pharmacists will be able to help with patient education and support regarding medical cannabis. In addition, with one of the pharmacies occupying a space of over 6,000 square feet, we have the potential to open a new medical and/or cannabis clinic within the existing space.”
Is Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) set to become the next market leader? Take a look at Teladoc Health Inc. (TDOC), a company which currently services over 130 countries around the world. It reported Q4 and full-year 2018 results  that showed revenue increased by nearly 80% for the year! While this is impressive on its own, you may want to take a look at another important figure: total telemedicine visits grew by 80%.
The company made headlines after inking a deal with CVS Health to provide virtual healthcare offerings for patients with minor illnesses from their mobile device. While this is great news for Teladoc, this could be even greater news for Premier Health and here’s why: Companies at the forefront of the healthcare industry revolution are working to develop more innovative care offerings to lower costs and increase access to care. Artificial intelligence, big data analytics, and telemedicine are helping to lead the way.
It’s not hard to believe that two of the best performing sectors in the market have been technology and healthcare. Premier Health Group Inc. (OTC: PHGRF) (CSE: PHGI) provides exposure to both of these sectors. Not only has it built a framework to expand its reach into the multi-million patient range but it has also strategically positioned itself for bigger opportunities in our opinion.
Being at the start of something is what many dreams of and Premier Health Group Inc. (OTC: PHGRF) / (CSE: PHGI) continues to expand its operations. The latest deal with CB2 Insights could set the standard for doctor/patient engagement & medical marijuana prescriptions.
The partnership with 360 Health brings the company to service a country that has over a billion people living there. And its continued expansion through acquisitions of companies adding new technologies, new patients, and access to more healthcare professionals could set the stage for something even greater for the company.
- World Population Stats http://www.un.org/en/development/desa/population/events/pdf/other/21/21June_FINAL%20PRESS%20RELEASE_WPP17.pdf
- Doctors per patient https://www.nationmaster.com/country-info/stats/Health/Physicians/Per-1%2C000-people
- The Growth of Canada’s Medical Cannabis Market https://newfrontierdata.com/marijuana-insights/canadian-market-projected-growth-2/
- Healthcare AR market Value https://www.grandviewresearch.com/press-release/global-augmented-reality-ar-virtual-reality-vr-in-healthcare-market
- Teladoc Financial Results https://www.fiercehealthcare.com/tech/teladoc-reports-significant-gains-revenue-virtual-visits-2018
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. FULL DISCLAIMER HERE
3 Penny Stocks Looking To Change The Biotech Industry
The world of biotech investing can be tricky. That’s particularly true when it comes to small-cap stocks in the industry. These companies often have terrific science, but no profits and little revenue; if any at all. But biotech stocks can offer true potential for investors who know what to look for.
Perhaps the best strategy for gaining exposure to this space is to look at early-stage, small-cap biotechs. By doing so, you put yourself at the front-line for cutting edge, experimental companies that could one day hit it big. Given this, here are 3 small-cap biotechs working to evolve in the biotech industry.
GT Biopharma Inc. (GTBP)
One company making groundbreaking developments in the biotechnology field is GT Biopharma Inc. (GTBP). GT Biopharma Inc. is an immune-oncology biotech company determined to create new treatments for cancer. In order to do this, the company leverages its proprietary TriKE technology to develop its pipeline. As of now, GT Biopharma has 6 treatment plans undergoing the clinical trial process.
So, what exactly is this TriKE technology platform? TriKE is actually an acronym for tri-specific killer engagers that are made to target NK’s or natural killer and tumor cells. Once they target NK cells, it binds to the CD16 receptor which makes a longer and stronger response compared to current treatment methods.
One use of TriKE has been to develop a way to target the HIV-Env protein. The design to do this is known as HIV-TriKE. As a matter of fact, the company recently announced data that showed the effectiveness of HIV-TriKE. It was shown that it enhanced NK cell cytokine production and effectively killed infected targets with HIV-Env.
“We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease and is able to kill HIV in the reservoir.” Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy,” expressed Anthony Cataldo, CEO and Chairman of GE Biopharma.
Conatus Pharmaceuticals Inc. (CNAT)
This next biotechnology company is known as Conatus Pharmaceuticals Inc. (CNAT). This company’s focus is different compared to GT Biopharma. It aims to treat chronic diseases that have a large unmet need. Its lead product candidate CTS-2090, inhibits IL-1β which treats inflammatory diseases.
In terms of news releases, the company has been slightly lackluster over the last two months. However, in early August Conatus released its Q2 financials which showed some profitability promise in its income statement.
Revenues increased and expenses decreased in Q2 2019 compared to Q2 2018 which significantly reduced the company’s net loss by $3.8 million. One potential hindrance factor in the financials could be Conatus’ consistently declining free cash flow.
Nuvectra Corporation (NVTR)
To top things off, we have a neurostimulation company known as Nuvectra Corporation (NVTR). The company has a commercial product called Algovita Spinal Cord Stimulation which treats chronic pain of the trunk and limbs. In addition to this, Nuvectra is awaiting FDA pre-market approval for its Virtis Sacral Neuromodulation which treats chronic urinary retention and overstive bladders.
Compared to Conatus, Nuvectra has produced recent news that investors can sink their teeth into. First off, the company appointed Jennifer Kosharek as CFO around a month ago. This is a strong appointment thanks to her 15+ years of accounting experience and other leadership positions with Nuvectra.
Furthermore, the company recently submitted its supplementary chemical composition and biocompatibility data to the FDA to support Virtis’ pre-market approval.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma Inc. (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma Inc. (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma Inc. (GTBP). Full Disclaimer Click Here
Are These Biotech Names On Your October Watch List?
Over the past two decades, the biotech sector has been one of the best sectors to watch. If experts are to be believed, then it is likely to continue to be a hot sector for the foreseeable future. However, biotech stocks require research and that can help when it comes to making a list of biotech stocks.
Once that is done, the investor needs to track the companies closely. Then it’s easier to decide upon the best course of action. Here is a look at three biotechnology penny stocks this month.
Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)
If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.
David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.
“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”
Over the last week, shares of PMCB stock have jumped from $0.0319 to highs of $0.0367 on Friday.
Biotech Stocks To Watch: Hepion Pharmaceuticals (HEPA)
The next biotech stock to watch is Hepion Pharmaceuticals Inc (NASDAQ:HEPA). The company is involved in manufacturing medicines meant for liver conditions emanating from non-alcoholic reasons. The company announced that its research article has been published by the highly influential peer-reviewed journal, the Journal of Pharmacology and Experimental Therapeutics.
The paper in question is titled “A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.” The study shows that Hepion’s product CRV431 could well be a solution for treating chronic diseases of the liver. The paper also stated that the medicine is suited to address a range of therapeutic needs.
Once the news broke, the company’s stock started soaring and soared over 43% at $3.58, well off the session high of $5.59.
Biotech Stocks To Watch: Protalix Biotherapeutics (PLX)
The other biotech stock that broke out more this week is Protalix Biotherapeutics Inc (NYSE:PLX). The company released data from the BRIDGE Phase 3 clinical study of its product PRX-102 and the revelations have proven to be highly encouraging. Out of a total of 22 patients who had been enrolled for the study, the data was gleaned from 16 of them.
The patients in question had been treated with PRX-102 for 12 months. The medicine is meant for treating Fabry disease and it has been revealed that there was an improvement in the function of kidneys in the patients. The stock soared by as much as 75% on Thursday and should definitely be on the watch lists of most investors.
Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here.
Stock Price Newsletter – October 18, 2019
Biotech ETF’s Just Hit New Highs: 3 Stocks To Watch
The biotech sector has a plethora of stocks though. Therefore, an investor needs to put in the necessary research. On that note, here is a look at three biotech stocks to watch as sector stocks enjoy a bull run in October.
In Case You Missed It: Sernova (SVA) (SEOVF) Finds C-Peptide In Phase I/II Fasting Patient
Sernova Corp. (SVA) (SEOVF) has detected enduring levels of C-peptide (measured up to 30 days and continuing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes.
These Healthcare & Biotech Stocks Deserve Your Attention This Month
The positive results provided a break for the sector. Furthermore, healthcare stocks have risen by 5.7% this year. The entire index has seen a nearly 20 percent gain, according to The Wall Street Journal. With this in mind, healthcare and biotechnology stocks are in focus this month.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Featured4 days ago
What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World!
Biotechnology1 week ago
Biotech Stocks In Focus Amid New Wave Of Drug Delivery
Biotechnology2 weeks ago
Top Biotechnology Stocks To Watch This Quarter
Biotechnology1 week ago
3 Top Biotech Stocks To Monitor In October
Biotechnology3 days ago
Healthcare Stocks To Watch Amid Bullish Earnings
Biotechnology2 weeks ago
Top Biotechnology Stocks To Watch After Latest News
Biotechnology2 days ago
Biotech Stocks To As Sector ETF’s Climb Higher
Biotechnology1 week ago
Biotechnology Stocks Gaining Ground In October; What To Watch